• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    12/25/23 12:30:49 PM ET
    $ALVR
    $BACK
    $CYCC
    $HOOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Health Care
    Get the next $ALVR alert in real time by email

    Gainers

    • Jin Medical International (NASDAQ:ZJYL) shares moved upwards by 94.4% to $137.0 during Monday's regular session. The market value of their outstanding shares is at $1.0 billion.
    • Karuna Therapeutics (NASDAQ:KRTX) stock increased by 47.71% to $317.87. The market value of their outstanding shares is at $11.9 billion.
    • IMAC Hldgs (NASDAQ:BACK) shares moved upwards by 42.59% to $2.31. The market value of their outstanding shares is at $2.6 million.
    • Pasithea Therapeutics (NASDAQ:KTTA) shares rose 32.86% to $0.38. The market value of their outstanding shares is at $7.9 million.
    • PureTech Health (NASDAQ:PRTC) stock moved upwards by 31.3% to $25.0. The market value of their outstanding shares is at $679.8 million.
    • Renalytix (NASDAQ:RNLX) shares increased by 30.4% to $0.45. The company's market cap stands at $22.4 million.

    Losers

    • AlloVir (NASDAQ:ALVR) stock fell 66.2% to $0.79 during Monday's regular session. The company's market cap stands at $89.7 million.
    • Cyclacel Pharmaceuticals (NASDAQ:CYCC) shares decreased by 23.89% to $2.74. The market value of their outstanding shares is at $2.3 million.
    • 60 Degrees (NASDAQ:SXTP) shares decreased by 17.28% to $0.91. The market value of their outstanding shares is at $5.2 million.
    • HOOKIPA Pharma (NASDAQ:HOOK) shares fell 16.41% to $0.72. The market value of their outstanding shares is at $60.5 million.
    • Theriva Biologics (AMEX:TOVX) shares fell 15.24% to $0.43. The company's market cap stands at $7.3 million.
    • Nanobiotix (NASDAQ:NBTX) stock declined by 14.72% to $6.55. The market value of their outstanding shares is at $308.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALVR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALVR
    $BACK
    $CYCC
    $HOOK

    CompanyDatePrice TargetRatingAnalyst
    Nanobiotix S.A.
    $NBTX
    2/6/2026Buy
    TD Cowen
    HOOKIPA Pharma Inc.
    $HOOK
    12/20/2024$48.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    HOOKIPA Pharma Inc.
    $HOOK
    11/15/2024$50.00 → $48.00Outperform
    RBC Capital Mkts
    PureTech Health plc
    $PRTC
    9/9/2024$58.00 → $45.00Outperform
    Leerink Partners
    Nanobiotix S.A.
    $NBTX
    8/28/2024$12.00Buy
    Guggenheim
    AlloVir Inc.
    $ALVR
    12/26/2023$17.00 → $1.00Buy → Underperform
    BofA Securities
    AlloVir Inc.
    $ALVR
    12/22/2023Outperform → Market Perform
    Leerink Partners
    AlloVir Inc.
    $ALVR
    12/22/2023Overweight → Underweight
    JP Morgan
    More analyst ratings

    $ALVR
    $BACK
    $CYCC
    $HOOK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Nanobiotix

    TD Cowen initiated coverage of Nanobiotix with a rating of Buy

    2/6/26 8:11:18 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded HOOKIPA Pharma from Outperform to Sector Perform and set a new price target of $2.00 from $48.00 previously

    12/20/24 7:37:05 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts reiterated coverage on HOOKIPA Pharma with a new price target

    RBC Capital Mkts reiterated coverage of HOOKIPA Pharma with a rating of Outperform and set a new price target of $48.00 from $50.00 previously

    11/15/24 11:07:50 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALVR
    $BACK
    $CYCC
    $HOOK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CEO and CFO Shallcross Steven A

    4 - Theriva Biologics, Inc. (0000894158) (Issuer)

    1/6/26 4:55:21 PM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Monahan John J

    4 - Theriva Biologics, Inc. (0000894158) (Issuer)

    1/6/26 4:54:19 PM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Kraws Jeffrey J

    4 - Theriva Biologics, Inc. (0000894158) (Issuer)

    1/6/26 4:53:11 PM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALVR
    $BACK
    $CYCC
    $HOOK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

    All three patients enrolled in study have been cured, confirming high cure rate of tafenoquine in immunosuppressed patients, as reported by Yale in a 2024 publicationCompany calls for existing babesiosis treatment guidelines to be reviewed in light of the new data WASHINGTON, March 11, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that three of three enrolled patients have been cured of babesiosis after completing the tafenoquine regimen in the Company's trial of relapsing babesiosis in immunosuppressed patients. The Com

    3/11/26 7:24:00 AM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NANOBIOTIX to Participate in Investor Conferences in March

    PARIS and CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ:NBTX - the "Company"), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in these upcoming conferences in March: TD Cowen's Health Care ConferenceDate: Wednesday, March 4, 2026Location: Boston, MATime of the fireside chat: 11:10am ET / 5:10pm CETPresenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix UBS Biotech Summit Miami Date: Monday, March

    2/25/26 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech to Present at the Leerink Partners Global Healthcare Conference

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced that Robert Lyne, Chief Executive Officer, and Eric Elenko, PhD, Co-founder and President, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026, at 11:20am EDT. A webcast of the presentation will be available at https://investors.puretechhealth.com. About PureTech Health PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this thr

    2/25/26 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALVR
    $BACK
    $CYCC
    $HOOK
    SEC Filings

    View All

    SEC Form PRE 14A filed by Theriva Biologics Inc.

    PRE 14A - Theriva Biologics, Inc. (0000894158) (Filer)

    3/4/26 4:35:21 PM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by 60 Degrees Pharmaceuticals Inc.

    424B5 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

    3/2/26 4:20:12 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMAC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - IMAC Holdings, Inc. (0001729944) (Filer)

    2/27/26 4:00:35 PM ET
    $BACK
    Medical Specialities
    Health Care

    $ALVR
    $BACK
    $CYCC
    $HOOK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Dow Geoffrey S bought $7,759 worth of shares (9,670 units at $0.80), increasing direct ownership by 19% to 59,618 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    12/16/25 5:41:35 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Dow Geoffrey S bought $12,204 worth of shares (12,963 units at $0.94), increasing direct ownership by 35% to 49,948 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    12/12/25 8:39:45 AM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Steinman Lawrence bought $100,000 worth of shares (133,333 units at $0.75), increasing direct ownership by 201% to 199,691 units (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 9:07:14 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALVR
    $BACK
    $CYCC
    $HOOK
    Leadership Updates

    Live Leadership Updates

    View All

    PureTech Appoints Robert Lyne as Chief Executive Officer

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announces that the Board of Directors has appointed Robert Lyne as Chief Executive Officer (CEO), and as a member of the Board of Directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251217152848/en/Robert Lyne, Chief Executive Officer of PureTech Robert Lyne commented: "I'm honored to lead PureTech as CEO at such an important moment in its evolution. Over the past two years, I've seen first-hand the streng

    12/18/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris

    PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) --  NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that following the annual review of the Euronext Paris indices, the Scientific Council of the Indices has decided to admit Nanobiotix to both the CAC Mid 60 and SBF 120 indices. These changes will become effective after the market closes on Friday, December 19, 2025. The CAC Mid 60 and SBF 120 indices represent two of the most widely followed benchmarks for mid-sized and leading liste

    12/15/25 2:30:00 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Announces Leadership Transition

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announces that Bharatt Chowrira, PhD, JD, has stepped down today from his role as Chief Executive Officer (CEO) and as a member of the Board of Directors. The Board of Directors has appointed Robert Lyne as Interim CEO with effect from today. Mr. Lyne joined PureTech as Chief Portfolio Officer in January 2024 and is an experienced leader of UK-listed life science innovation and venture capital companies, having previously served as CEO of Arix Bioscience plc. He will continue to work closely with PureTe

    7/16/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALVR
    $BACK
    $CYCC
    $HOOK
    Financials

    Live finance-specific insights

    View All

    NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1

    Data show a favorable safety profile and early efficacy signals in a heavily pre-treated population whose cancer progressed after multiple prior lines of therapy including anti-PD-1Recommended phase 2 dose (RP2D) established at 33% of gross tumor volume (GTV)47.4% (9/19) best observed objective response rate (ORR) in all lesions per RECIST 1.178.9% (15/19) best observed disease control rate (DCR) in all lesions per RECIST 1.114.6 months median Overall Survival (mOS) in all patients treated (n=21)Investigators concluded that these data warrant further investigation in randomized clinical trials as a potential new option for patients with primary cutaneous melanoma naïve or refractory to anti-

    9/17/25 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Health: Notice of Half-Yearly Results

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company") plans to announce its half-yearly results for the six months ended June 30, 2025, on Thursday, August 28, 2025. A presentation and conference call for analysts and shareholders will take place at 9:00am EDT / 2:00pm BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep port

    8/18/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

    KUALA LUMPUR, Malaysia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative medicines, today announced its second quarter financial results and provided a business update. Highlights of the second quarter ended June 30, 2025, or in some cases shortly thereafter, include: In April, the Company announced that the Board of Directors of the Company declared a quarterly cash dividend of $0.15 per share on the Company's 6% Convertible Exchangeable Preferred Stock, which cash dividend was paid on May 1, 2025, to holders of 6% Convertible Exchangeable P

    8/13/25 4:05:00 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALVR
    $BACK
    $CYCC
    $HOOK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cyclacel Pharmaceuticals Inc.

    SC 13G/A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)

    11/14/24 7:21:58 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by HOOKIPA Pharma Inc.

    SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

    11/14/24 6:07:08 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by 60 Degrees Pharmaceuticals Inc.

    SC 13G - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

    11/14/24 3:37:18 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care